EGFR and esophageal cancer: This innovative nanoscale radiosensitizer has demonstrated increased sensitization rates of 1.32-fold in EGFR-overexpressing esophageal cancer cells and 1.25-fold in EGFR-low-expressing cells compared to paclitaxel alone suggesting that this strategy has the potential to overcome the current limitations in esophageal cancer treatment (Ai et al., 2018).